Edoxaban + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation
Trial Timeline
Mar 21, 2017 โ Sep 24, 2018
NCT ID
NCT02942576About Edoxaban + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen
Edoxaban + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen + VKA-Based Regimen is a phase 3 stage product being developed by Daiichi Sankyo for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT02942576. Target conditions include Atrial Fibrillation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02942576 | Phase 3 | Completed |
Competing Products
20 competing products in Atrial Fibrillation